Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Inozyme Pharma, Inc. (INZY : NSDQ)

• Company Description    Inozyme Pharma Inc. is a biopharmaceutical company. It engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue and skeleton diseases. The company's product candidate consist INZ-701, which is in clinical stage. Inozyme Pharma Inc. is based in Boston, Massachusetts. Number of Employees: 50

• Price / Volume Information    Yesterday's Closing Price: $4.22 Daily Weekly Monthly 20 Day Moving Average: 304,050 shares Shares Outstanding: 40.10 (millions) Market Capitalization: $169.21 (millions) Beta: 1.12 52 Week High: $19.58 52 Week Low: $3.54 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -14.23% -3.40% 12 Week -26.99% -19.74% Year To Date -38.12% -24.93%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 321 SUMMER STREET SUITE 400 - BOSTON,MA 02210 USA ph: 857-330-4340 fax: - ir@inozyme.com http://www.inozyme.com

• General Corporate Information    Officers Axel Bolte - Chief Executive Officer; President and Director Douglas Treco - Chairman Stephen DiPalma - Interim Chief Financial Officer Sarah Bhagat - Director Reinaldo Diaz - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 45790W108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/10/22 Share - Related Items Shares Outstanding: 40.10 Most Recent Split Date: (:1) Beta: 1.12 Market Capitalization: $169.21 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.49 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.33 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 22.59% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/10/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.80 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -51.06% vs. Previous Quarter: 10.13% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - -53.41 12/31/21 - -43.36 09/30/21 - -34.30 ROA 03/31/22 - -48.19 12/31/21 - -39.84 09/30/21 - -31.90 Current Ratio 03/31/22 - 8.20 12/31/21 - 9.92 09/30/21 - 14.60 Quick Ratio 03/31/22 - 8.20 12/31/21 - 9.92 09/30/21 - 14.60 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - 2.35 12/31/21 - 4.62 09/30/21 - 5.32 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©